Officials debate whether to scrap malaria program

October 31, 2012 by Maria Cheng
In this Aug. 26, 2009 file photo, a merchant speaks with a woman holding her ill child at a pharmacy in Pailin, Cambodia. The future of a pricey malaria program meant to provide cheap drugs for poor patients may be in jeopardy after health officials clashed over its effectiveness in two new reports. In 2010, the Affordable Medicines Facility for malaria was started by groups including United Nations agencies and the Global Fund to Fight AIDS, Tuberculosis and Malaria. It was a pilot project to subsidize artemesinin combination drugs. Most of the drugs bought were sold in the private sector, where there are few controls on who gets them. But in October 2012, a report by Oxfam, an international charity, labeled the program a failure and said there was no proof it had saved lives because officials didn't track who received the drugs. (AP Photo/David Longstreath, File)

The future of a pricey malaria program meant to provide cheap drugs for poor patients may be in jeopardy after health officials clashed over its effectiveness in two new reports.

In 2010, the Affordable Medicines Facility for was started by groups including United Nations agencies and the to Fight AIDS, Tuberculosis and Malaria. It was a to subsidize artemesinin combination drugs, the most effective .

The initiative cost more than $460 million, mostly funded by the Global Fund, UNITAID, and the Canadian and British governments. It was tested in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania and Uganda. Most of the drugs bought were sold in the private sector, where there are few controls on who gets them.

Last week, a report by Oxfam, an international charity, labeled the program a failure and said there was no proof it had saved lives because officials didn't track who received the drugs.

"It's time for this to be scrapped," said Mohga Kamal-Yanni, the paper's author. "If you subsidize drugs and make them cheap, then clearly the supply will increase. But we have no idea whether the drugs are getting to the right people."

According to the , "improving the rational use of (malaria drugs) was not a specific strategic objective" of the program. In a statement, the agency said there was limited information about how many children under five—those most susceptible to malaria—received the subsidized drugs.

"No information has been made available on the use of these medicines by the poorest communities," WHO said.

But in another paper published Wednesday in the , experts insisted the program was "an effective mechanism" to lower the price of preferred malaria drugs and make them widely available.

That study didn't include Cambodia and found that everywhere except for Niger and Madagascar, there was a bigger supply of the medicines. Researchers didn't measure whether that lowered the number of malaria cases. The study was paid for by the Global Fund and the Bill & Melinda Gates Foundation.

The Global Fund called the program "a practical approach to fighting disease" and said the were not previously available in many African communities. "The reality of this program is that it is getting life-saving medicine to people who need it most from the private sector outlets where they already seek treatment," the fund said in a statement.

Others suggested the initiative be overhauled.

"We have had caveats about this program since the beginning," said Manica Balasegaram, an executive director at Medecins Sans Frontieres, which is not linked to either report.

He said it was important to use diagnostic tests before giving out malaria medicines, to ensure that people who took them actually had malaria. Giving the drugs to people without the disease could worsen resistance and wouldn't cure whatever ailment they did have. "If this program continues, we would like to see serious changes made," Balasegaram said.

Next month, Global Fund officials and others will discuss the program's fate at a previously scheduled meeting.

Since the program's inception, the U.S. President's Malaria Initiative, the world's second-biggest donor to malaria control after the Global Fund, has requested compelling evidence the subsidy program works. Without that, the U.S. group said it is not allowed by law to finance the malaria project. WHO has described the program's future as uncertain.

David Schellenberg, a public health expert at the London School of Hygiene and Tropical Medicine, said it was too early to judge if the program had succeeded. "More people might be inadequately treated if this program is closed," he said. "But this approach will not work everywhere."

Explore further: Malaria on way out in third of nations hit: study

More information:
www.lancet.com
www.oxfam.org
www.theglobalfund.org

shares

Related Stories

Malaria on way out in third of nations hit: study

October 17, 2011
Nearly a third of all nations in which malaria is endemic are working to eliminate the disease within a decade, according to a new report released Monday in the United States.

Some WHO-approved malaria drugs fall short: study

July 10, 2012
Up to eight percent of malaria drugs approved by the World Health Organization or other regulators do not contain the right dose and may fuel resistance, researchers said Tuesday.

Recommended for you

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Gastric acid suppressant lansoprazole may target tuberculosis

November 21, 2017
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause tuberculosis (TB), according to new research from UCL and the London School of Hygiene ...

Improving prediction accuracy of Crohn's disease based on repeated fecal sampling

November 21, 2017
Researchers at the University of California San Diego Center for Microbiome Innovation (CMI) have found that sampling the gut microbiome over time can provide insights that are not available with a single time point. The ...

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.